Applications of Imidurea NF in Industrial Manufacturing

Imidurea NF is a pharmaceutical-grade preservative serving regulated industrial sectors. Below, we highlight specific downstream uses across medical, personal care, and technical manufacturing, detailing process integration and regulatory requirements for each application scenario.

1. Pharmaceutical Creams and Ointments Production

Pharmaceutical manufacturers frequently use this preservative in topical creams and ointments to inhibit microbial contamination during storage and use. It performs well in water-based semi-solid formulations, supporting extended shelf life in non-sterile dermatological preparations. QC laboratories verify its concentration as part of routine lot release, ensuring drug product safety for patients. GMP-compliant process design necessitates staged addition during the cooling phase to preserve its stability.

Industry compliance standards

• USP-NF Monograph for Imidurea
• 21 CFR 330.1 (US FDA regulations for topical OTC drugs)
• EU GMP (EudraLex, Volume 4)
• ICH Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and Products

Typical usage ratio

• 0.3%–0.6% w/w total batch mass, determined by product matrix and final water activity

Downstream process integration

• Added post-emulsification, cooling the formulation below 50°C before dosing, followed by homogenization for uniform distribution

Final product types

• Prescription corticosteroid creams
• Over-the-counter antifungal ointments
• Dermatology combination gels
• Moisturizing barrier creams for hospital use

2. Ophthalmic Solution Manufacturing

The eye care sector includes this preservative in multidose eye drop preparations to suppress gram-positive and gram-negative bacterial growth. Facilities using aseptic filling integrate dedicated pre-diluted stock solutions to control preservative distribution. Product development teams must balance preservative efficacy with ocular tolerability, following compendial preservative challenge testing for each formula variant before market release.

Industry compliance standards

• USP 771 Ophthalmic Preparations
• 21 CFR 200.50 (US FDA regulations regarding ophthalmic products)
• EP Ph. Eur. Monograph 0269: Ophthalmic Preparations
• WHO Good Manufacturing Practices for Sterile Pharmaceutical Products

Typical usage ratio

• 0.3%–0.4% w/v in finished product; concentration adjusted based on preservative-neutralizing excipient profiles

Downstream process integration

• Dosed as an aqueous concentrate after final filtration, before aseptic transfer to the filling line; preservative effectiveness validated with in-process bioburden and preservative challenge assays

Final product types

• Lubricating artificial tear drops
• Allergy relief ophthalmic solutions
• Antimicrobial eye washes in multidose containers

3. Personal Care Creams and Lotions Manufacturing

Personal care producers incorporate Imidurea NF as a broad-spectrum antimicrobial preservative in cosmetic creams, body lotions, and hand-care emulsions. Formulators select preservative thresholds depending on pH and oil phase composition, always validating preservative stability under accelerated shelf-life studies. Manufacturing lines dose it in the cooling phase to prevent volatilization loss, and QA teams conduct microbiological testing on every filling batch to comply with global cosmetics regulations.

Industry compliance standards

• EU Cosmetics Regulation (EC No 1223/2009)
• ASEAN Cosmetic Directive
• US FDA 21 CFR 700 Subpart B
• ISO 22716: Cosmetics — Good Manufacturing Practices

Typical usage ratio

• 0.2%–0.5% w/w, chosen based on water activity and exposure to consumer handling

Downstream process integration

• Introduced as a post-cooling addition, maintained below 45°C before final homogenization; monitored by preserved efficacy testing in bulk tanks

Final product types

• Facial and body lotions
• Hand creams
• Emollient balms
• Personal care wipes

4. Oral Care Paste and Gel Processing

Oral hygiene product manufacturers rely on this raw material to ensure microbiological control in fluoride gels and medical toothpastes. Integration occurs during the aqueous phase mixing, prior to thickener hydration, so the preservative disperses fully. Facilities observe national food safety and oral hygiene regulations, performing routine challenge tests with regulatory reference strains to confirm formula compliance.

Industry compliance standards

• FDA Food Additive Status List
• ISO 16128: Guidelines on technical definitions and criteria for natural and organic cosmetic ingredients and products
• GB 8372-2017 (China National Standard for Toothpaste)
• EU Cosmetics Regulation (Annex V preservative lists)

Typical usage ratio

• 0.3%–0.5% w/w, adjusted for water content and pH of the formula

Downstream process integration

• Blended into the deionized aqueous phase before binder addition; in-line QC checks for uniformity; monitored for preservative activity throughout storage

Final product types

• Fluoride dental gels
• Whitening toothpaste pastes
• Chlorhexidine oral cleansing gels
• Medical desensitizing pastes

5. Veterinary Topical Preparation Manufacturing

Veterinary pharmaceutical plants use Imidurea NF as an antimicrobial preservative in topical gels, creams, and wound care sprays for companion and livestock animals. Formulators must document preservative content in regulatory dossiers, justifying selections based on risk analysis for the intended animal species. Process engineers add it during the aqueous mixing phase to prevent post-processing contamination, with QA teams running periodic preservative efficacy tests under VICH guidelines.

Industry compliance standards

• VICH GL40: Pharmacovigilance of Veterinary Medicinal Products
• EU Regulation 2019/6 on Veterinary Medicinal Products
• AVMA (American Veterinary Medical Association) Guidelines for Drug Compounding
• FDA Center for Veterinary Medicine (CVM) Guidance for Industry

Typical usage ratio

• 0.25%–0.45% w/w, titrated based on dosage form and expected shelf-life temperature stability

Downstream process integration

• Introduced during water phase mixing; final content checked in filled containers; periodic challenge studies for pathogen resistance

Final product types

• Pet wound treatment creams
• Livestock dermatological gels
• Topical antiseptic sprays for farm use
• Compounded veterinary ointments

6. Diagnostic Gel and Solution Manufacturing

Medical device and diagnostics manufacturers incorporate this ingredient in specimen transport media, diagnostic gels, and staining solutions for laboratory applications. The preservative hinders cross-contamination by opportunistic microorganisms, particularly during long-term storage and sample transport. Material handling protocols require separate dosing reservoirs; batch records document preservative addition as a critical control step. QA performs lot-based challenge and stability studies, complying with laboratory reagent standards.

Industry compliance standards

• ISO 13485: Medical Devices — Quality Management Systems
• US CLIA (Clinical Laboratory Improvement Amendments)
• IVD Directive 98/79/EC (EU In Vitro Diagnostic Medical Devices Regulation)
• CAP (College of American Pathologists) Accreditation Checklists

Typical usage ratio

• 0.25%–0.55% w/w, established during method development as per microbial stability requirements

Downstream process integration

• Dosed into aqueous diagnostic mixture immediately before filling; monitored by simulated transport stability studies over shelf life

Final product types

• Specimen collection media
• Microbiology diagnostic gels
• Histological staining solutions
• Transportable laboratory reagents